How Do Tharimmune Inc (NASDAQ:THAR)’s Fundamentals Affect Performance

In yesterday’s Wall Street session, Tharimmune Inc (NASDAQ:THAR) shares traded at $0.20, down -23.08% from the previous session.

1 analysts cover Tharimmune Inc (NASDAQ:THAR), according to research data. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $4.00 and a low of $4.00, we find $4.00. Given the previous closing price of $0.26, this indicates a potential upside of 1438.46 percent. THAR stock price is now -3.16% away from the 50-day moving average and -63.64% away from the 200-day moving average. The market capitalization of the company currently stands at $3.36M.

The stock has received a hold rating from 1 analysts and a buy rating from 0. Brokers who have rated the stock have averaged $4.00 as their price target over the next twelve months.

A total of 24.57% of the company’s stock is owned by insiders.

On Wednesday morning Tharimmune Inc (NASDAQ: THAR) stock kicked off with the opening price of $0.2418. During the past 12 months, Tharimmune Inc has had a low of $0.14 and a high of $2.65. As of last week, the company has a debt-to-equity ratio of 0.10, a current ratio of 3.01, and a quick ratio of 3.01. The fifty day moving average price for THAR is $0.2065 and a two-hundred day moving average price translates $0.5501 for the stock.

The latest earnings results from Tharimmune Inc (NASDAQ: THAR) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.16, inline with analysts’ expectations of -$0.16. This compares to -$0.18 EPS in the same period last year. The company reported revenue of $1.84 million for the quarter, compared to $2.13 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -13.3 percent.

Tharimmune Inc(THAR) Company Profile

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company’s pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059, product candidates used to treat various solid tumors; and TH1940, which targets PD-1. It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Related Posts